PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2015.
“We continue to make significant progress in developing and commercializing innovative new products derived from our boron chemistry platform. In the third quarter, we announced positive top-line results from our two Phase 3 pivotal studies of crisaborole for the potential treatment of mild-to-moderate atopic dermatitis in children and adults, and last week we announced the top-line results from our long-term safety study of crisaborole that demonstrated a safety profile consistent with that seen in our Phase 3 pivotal studies.
Help employers find you! Check out all the jobs and post your resume.
